Clinical Trials Logo

Clinical Trial Summary

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06194799
Study type Interventional
Source ACADIA Pharmaceuticals Inc.
Contact
Status Enrolling by invitation
Phase Phase 3
Start date April 23, 2024
Completion date May 2029

See also
  Status Clinical Trial Phase
Completed NCT02035553 - A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis Phase 2
Recruiting NCT06159673 - ACP-204 in Adults With Alzheimer's Disease Psychosis Phase 2/Phase 3